Drug Trial Radar · NCT03980730
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
Last checked: Nov 19, 2026Latest source record: Jan 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
43
Actual
Start
Jun 27, 2019
Primary completion
Dec 1, 2020
Study completion Jan 29, 2021
Sponsor
- Lead sponsor
- vTv TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 9 months (in Part 1) or 21 months (in Part 2).
Conditions
- Alzheimer Disease
Interventions
AzeliragonDrug
Azeliragon 5 mg capsule administered orally, once daily
PlaceboDrug
Matching placebo capsule administered orally, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 : Change From Baseline in the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog14) at Month 6Time frame: Baseline to Month 6
Locations
33 sites in 2 countries. Site status is shown where the registry gives one.
Tucson Neuroscience Research
Tucson, Arizona
Institute for Neurodegenerative Disorders
New Haven, Connecticut
JEM Research Institute
Atlantis, Florida
Brain Matters Research
Delray Beach, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Charter Research
Lady Lake, Florida
Alzheimer's Research and Treatment Center
Lake Worth, Florida
ClinCloud
Maitland, Florida
Synexus Clinical Research US
Orlando, Florida
Emerald Coast Center for Neurological Disorders
Pensacola, Florida
Progressive Medical Research
Port Orange, Florida
The Roskamp Institute
Sarasota, Florida
Brain Matters Research
Stuart, Florida
Emory Alzheimer's Clinical Research Unit
Atlanta, Georgia
NeuroStudies.net LLC
Decatur, Georgia
IU Health Partners, Adult Neurology Clinic
Indianapolis, Indiana
Memory Center / Hattiesburg Clinic
Hattiesburg, Mississippi
Millennium Psychiatric Associates
St Louis, Missouri
The Cognitive and Research Center of New Jersey
Springfield, New Jersey
Clarity Clinical Research
East Syracuse, New York
Neurological Associates of Long Island
Lake Success, New York
ANI Neurology dba Alzheimer's Memory Center
Charlotte, North Carolina
Raleigh Neurology Associates
Raleigh, North Carolina
Wake Forest School of Medicine
Winston-Salem, North Carolina
The Ohio State University
Columbus, Ohio
Summit Research Network
Portland, Oregon
Center for Cognitive Health
Portland, Oregon
Okanagan Clinical Trials Ltd.
Kelowna, British Columbia, Canada
True North Clinical Research Inc.
Halifax, Nova Scotia, Canada
True North Clinical Research Inc.
Kentville, Nova Scotia, Canada
Recherches Neuro-Hippocampe
Ottawa, Ontario, Canada
Recherches Neuro-Hippocampe Inc.
Gatineau, Quebec, Canada
Q&T Research Sherbrooke Inc
Sherbrooke, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.